Optimizing RSV Protection for All Infants

CAN-eng

$0

free

Unaccredited

1 hr

Infectious Disease,Respirology

0 Credits

Course Description

Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by two years of age. RSV accounts for a significant burden of disease in infants and young children, causing serious complications for infants, including hospitalization, as well as significant impact on caregivers and families. Although the risk of severe RSV disease is higher in infants with certain medical conditions including prematurity, full-term infants account for the highest proportion of infants with severe RSV disease. In order to address this substantial disease burden, NACI has recently issued new guidance for RSV immunoprophylaxis for all infants with a focus on the use of nirsevimab to prevent severe RSV disease. In 2023, Health Canada authorized two new RSV immunoprophylaxis: nirsevimab, a long-acting monoclonal antibody, and RSVpreF, a maternal vaccine. NACI guidelines state that nirsevimab is currently preferred over RSVpreF due to its higher efficacy and possible longer duration of protection.


This program has received an unrestricted educational grant or in-kind support from Sanofi.

Course Details

Expiry Date: 2025-08-12
Professions: Physician,Nursing,Pharmacy,Allied Health,Medical Resident,Student,Specialist

Faculty

  • Marc Lebel, MD, FRCPC
  • Christine Palmay, HBArtSci, MD, CCFP, FCFP
  • Erin Fleischer, RN (EC) NP Paeds, BSCN, MN, ACNP
  • Ronik Kanani, MD

Accreditation

Learning Objectives

Upon completion of this continuing education program participants will be better able to:

  • Cite the prevalence and burden of RSV disease in infants
  • Evaluate clinical and safety data of recently approved RSV immunoprophylaxis for infants
  • Summarize NACI guidance on RSV immunoprophylaxis for all infants
  • Implement RSV immunoprophylaxis for infants in clinical practice